Recurrent Adult Acute Myeloid Leukemia

Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bio-Path Holdings
Bio-Path HoldingsBELLAIRE, TX
1 program
1
BP1001Phase 11 trial
Active Trials
NCT01159028CompletedEst. Mar 2017
HM
Huadong MedicineChina - Hangzhou
1 program
CMGVN/A1 trial
Active Trials
NCT06329999RecruitingEst. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Bio-Path HoldingsBP1001
Huadong MedicineCMGV

Clinical Trials (2)

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Start: Jun 2010Est. completion: Mar 2017
Phase 1Completed

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Start: Feb 2024Est. completion: Dec 2027
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
2 companies competing in this space